Tvardi Q1 net loss narrows to $6.8M; TTI-109 data due June, TTI-101 HCC data 2H 2026

Tvardi Therapeutics, Inc.

2026-Q1 EPS reported -$0.73

Net loss of $6.8M ($0.73 per share) vs $9.6M ($3.72) in Q1 2025; R&D spend rose to $4.9M.
Cash, cash equivalents and ST investments $25.0M at March 31, 2026; runway through Q4 2026.
TTI-109 Phase 1 healthy volunteer topline data and development strategy expected June 2026.
TTI-101 Phase 2 HCC topline data on track for 2H 2026; IPF fibrosis score reduction 9.4% vs 2.4% placebo.
TTI-109 is a next-generation STAT3 prodrug designed for improved tolerability vs TTI-101.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Tvardi Therapeutics, Inc. reported first quarter ended March 31, 2026 results: net income $6.8 million, EPS $(0.73).

Period: first quarter ended March 31, 2026
Net income: $6.8 million
EPS: $(0.73)
Result: reported results

Exact text from the filing

Net loss for the three months ended March 31, 2026, was $6.8 million, as compared to a net loss of $9.6 million for the comparable period in 2025. Basic and diluted net loss per share attributable to common shareholders for the three months ended March 31, 2026, were a net loss of $(0.73), compared to a net loss of $(3.72) for the comparable period in 2025.

View on SEC.gov

Browse all earnings releases →

Tvardi Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-057524

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.